Open Your FREE Demat Account Now!

Aurobindo Pharma Ltd. Share Price

NSE
BSE

NSE : AUROPHARMA

BSE : 524804

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹1,633.00

High

₹1,697.90

Price Summary

Previous Close ₹1,693.00
Day's Range ₹1,633.00 - ₹1,697.90
Open ₹1,645.90
52 Week Range ₹1,080.10 - ₹1,740.00
Volume 6,99,038
Market Cap ₹0.10
Previous Close ₹1,686.10
Day's Range ₹1,633.35 - ₹1,697.30
Open ₹1,642.05
52 Week Range ₹1,080.10 - ₹1,739.95
Volume 13,288
Market Cap ₹0.10

Stocks Summary

Trade Value ( ₹ in Lacs) 11,745.12
Market Cap (₹ in Mn) 0.10
Dividend Yield(%) 0.24
Price/Earning (TTM) 26.13
TTM EPS (₹) 64.52
P/E Ratio 21.60
Book Value(₹) 2.49
PAT Margin (%) 5.04
Face Value (₹) 1.00
ROCE(%) 12.76
Trade Value ( ₹ in Lacs) 221.51
Market Cap (₹ in Mn) 0.10
Dividend Yield(%) 0.24
Price/Earning (TTM) 26.13
TTM EPS (₹) 64.52
P/E Ratio 21.60
Book Value(₹) 2.49
PAT Margin (%) 5.04
Face Value (₹) 1.00
ROCE(%) 12.76

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 78681.4 109333.0
Expenses N/A N/A
PBT 12068.0 23584.5
Operating profit 0.0 0.0
Net profit 8242.0 17467.9

Shareholding Pattern

Promoters (% Holding)

51.88%

Mutual funds (% Holding)

16.71%

Non-Institution (% Holding)

6.64%

FI/Banks/Insurance (% Holding)

4.99%

Government (% Holding)

0.00%

FII

16.38%

About Aurobindo Pharma Ltd.

Founded 1986
Managing Director K Nityananda Reddy
NSE Symbol AUROPHARMA

Latest News

Oct
9
2026
EQUITY Posted on Oct 9th 2026

Aurobindo Pharma informs about newspaper publication

Aurobindo Pharma has enclosed the copies of notice published by the Company on October 9, 2026, in Business Standard and Nava Telangana (Telugu) regarding special window for re-lodgement of transfer requests of physical shares.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
3
2026
EQUITY Posted on Oct 3rd 2026

Aurobindo Pharma informs about acquisition

Aurobindo Pharma has informed that this is with refer to letters dated July 23, 2026, September 12, 2026 and October 01, 2026, informing that Apitoria Pharma Private Limited (Apitoria), a wholly owned subsidiary of the Company, is acquiring the Contract Research Services business of A1 Biochem Group. A1 Biochem USA Inc (A1 USA Inc), which is a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited (A1 Labs India), has acquired 100% ownership of A1 Biochem Labs LLC (A1 Labs LLC) in accordance with the terms of the Definitive Agreements entered into for the acquisition of A1 Biochem Group. A1 Labs LLC is operating from USA and will now be a step-down subsidiary of A1 Labs India. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as Annexure A.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
24
2026
EQUITY Posted on Sep 24th 2026

Aurobindo Pharma informs about closure of trading window

Aurobindo Pharma has informed that as per the Company’s Internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the Trading Window for dealing in the securities of the Company would remain closed for all designated persons including Promoters, Directors, Key Managerial Personnel, Employees, Connected Persons and their immediate relatives with effect from October 1, 2026 till 48 hours after the declaration of the Unaudited Financial Results of the Company for the second quarter and half year ending on September 30, 2026. The date of the Board Meeting for declaration of the financial results of the Company for the second quarter and half year ending on September 30, 2026, will be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
15
2026
EQUITY Posted on Sep 15th 2026

Aurobindo Pharma informs about press release

Aurobindo Pharma has informed that it enclosed a copy of the Press Release that is being issued by the Company in connection with receipt of USFDA Final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
1
2026
EQUITY Posted on Sep 1st 2026

Aurobindo Pharma informs about disclosure

Aurobindo Pharma has informed that, Pharma Private, a wholly owned subsidiary of the Company has incorporated a new wholly owned subsidiary by the name of ‘Avogent Lifesciences’ in India. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure A’.

The above information is a part of company’s filings submitted to BSE.

Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Aurobindo Pharma Ltd. ?

The current share price of Aurobindo Pharma Ltd. is ₹1,693.00 as of 2026-10-09.

The market capitalisation of Aurobindo Pharma Ltd. is ₹97,014.47 as of 2026-10-09.

The 1-year return of Aurobindo Pharma Ltd. is 562.70% as of 2026-10-09.

The P/E ratio of Aurobindo Pharma Ltd. is 21.60 as of 2026-10-11.

The 52-week high and low of Aurobindo Pharma Ltd. are ₹1,740.00 and ₹1,080.10, respectively, as of 2026-10-09.

The dividend yield of Aurobindo Pharma Ltd. is 0.2372% as of2026-10-09.

You can buy Aurobindo Pharma Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Aurobindo Pharma Ltd. is K Nityananda Reddy.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore